10 Bristol Myers Squibb regulatory affairs leaders
Shih-Yi Kim, Executive Director Regulatory Affairs, leads this list of Bristol Myers Squibb regulatory affairs leaders, whose other titles cover global regulatory strategy, cell therapy, oncology and US commercial regulatory affairs. A reader can learn how regulatory affairs leaders work at Bristol Myers Squibb from people who have held the role.
Professionals to explore
Adrian Cheung, Ph.D., RAC
LinkedInExperience: Director, Regulatory Affairs, Oncology · Bristol Myers Squibb
Adrian Cheung has been Director, Regulatory Affairs, Oncology at Bristol Myers Squibb since January 2019, based in Glen Rock, New Jersey. Adrian Cheung was Senior Associate Director, Regulatory Affairs at Boehringer Ingelheim from 2017 to 2019 and Associate Director, Regulatory Affairs there from 2013 to 2017, and was Section Head, Drug Discovery at Roche from 2010 to 2012.
Brittany Dustman, PharmD, MS, RAC
LinkedInExperience: Director, Global Regulatory Affairs - Cell Therapy · Bristol Myers Squibb
Brittany Dustman has been Director, Global Regulatory Affairs - Cell Therapy at Bristol Myers Squibb since February 2022, based in Greater Philadelphia. At GSK, Brittany Dustman was Associate Director, Global Regulatory Affairs - Oncology, Cell and Gene Therapy from 2020 to 2022, Manager Global Regulatory Affairs from 2018 to 2020 and Postdoctoral Global Regulatory Affairs Fellow from 2016 to 2018.
Katherine Kim, Pharm.D.
LinkedInExperience: Director, US Commercial Regulatory Affairs · Bristol Myers Squibb
Katherine Kim has been Director, US Commercial Regulatory Affairs at Bristol Myers Squibb since July 2025, based in the New York City Metropolitan Area. At Bristol Myers Squibb, Katherine Kim was Associate Director, Commercial Regulatory Affairs - CAR T from 2020 to 2025 and Associate Director, Global Medical Information from 2018 to 2020.
Mary Vandekauter
LinkedInExperience: Director of Regulatory Affairs · Bristol Myers Squibb
Mary Vandekauter has been Director of Regulatory Affairs at Bristol Myers Squibb since November 2019, based in Prairie Village, Kansas. At Celgene, Mary Vandekauter was Director, Regulatory Affairs, Hematology/Oncology from 2014 to 2019, Director, Global Quality Product Steward from 2012 to 2014 and Associate Director, Global Regulatory CMC from 2008 to 2012.
Paula Egitto
LinkedInExperience: Senior Director Cell Therapy Global Regulatory Lead - Global Regulatory Strategy & Policy · Bristol Myers Squibb
Paula Egitto has been Senior Director Cell Therapy Global Regulatory Lead - Global Regulatory Strategy & Policy at Bristol Myers Squibb since August 2024, based in Chesterfield, New Jersey. At Bristol Myers Squibb, Paula Egitto held the titles Regulatory Affairs - Sr. Director GRS International (Europe & Intercontinental) Hematology Team Lead from 2023 to 2024 and Regulatory Affairs - Sr. Director GRS Intercontinental, CAR T and Hematology Lead from 2022 to 2023.
Petra Pavlickova
LinkedInExperience: Director, Global Regulatory Strategy · Bristol Myers Squibb
Petra Pavlickova has been Director, Global Regulatory Strategy at Bristol Myers Squibb since June 2022, based in San Diego, California. Petra Pavlickova held the title Associate Director Regulatory Affairs at Celgene from 2019 to 2022 and was Associate Director Regulatory Affairs at Conventus Biomedical Solutions, Inc. from 2018 to 2019 and Regulatory Affairs Manager at Grifols in 2017.
Priyanka Ingle
LinkedInExperience: Director, Regulatory Strategy · Bristol Myers Squibb
Priyanka Ingle has been Director, Regulatory Strategy at Bristol Myers Squibb since March 2024, based in the New York City Metropolitan Area, and the profile describes serving as US Lead for 4 therapeutic indications. Priyanka Ingle was Director, Global Regulatory Strategy at Bayer from 2020 to 2024 and VP, Translational Sciences and Regulatory Affairs at CRC Pharma from 2019 to 2020.
Saneta Chen
LinkedInExperience: Director, U.S. Commercial Regulatory Affairs Oncology · Bristol Myers Squibb
Saneta Chen has been Director, U.S. Commercial Regulatory Affairs Oncology at Bristol Myers Squibb since July 2025 and was Associate Director, U.S Commercial Regulatory Affairs there from 2021 to 2025, based in Princeton, New Jersey. Saneta Chen was Senior Scientific Manager, Global Medical Affairs, Oncology at AbbVie from 2018 to 2021.
Sarah (Feathers) Khan
LinkedInExperience: Executive Director, Immunology & Fibrosis Deputy Therapeutic Area Head, Global Regulatory Affairs · Bristol Myers Squibb
Sarah Khan has been Executive Director, Immunology & Fibrosis Deputy Therapeutic Area Head, Global Regulatory Affairs at Bristol Myers Squibb since October 2020, based in Greater Boston. The listing also shows Sarah Khan as Director, Global Regulatory Affairs, Oncology at Ipsen from 2017, and as Director, Global Regulatory Lead at Sanofi from 2015 to 2017.
Shih-Yi Kim
LinkedInExperience: Executive Director Regulatory Affairs · Bristol Myers Squibb
Shih-Yi Kim has been Executive Director Regulatory Affairs at Bristol Myers Squibb since May 2023 and was Senior Director Regulatory Affairs there from 2021 to 2023, based in the New York City Metropolitan Area. Shih-Yi Kim was Director of Regulatory Affairs at Amgen from 2019 to 2021 and Director of Regulatory Affairs at Celgene from 2018 to 2019.
Choose the right perspective
Match the scope named in a person's title, such as global regulatory strategy, cell therapy or US commercial regulatory affairs, to the question you need answered. Weigh how close the scope of each person's role is to the decision you face.
Questions to take into the conversation
- 01What did you focus on first when you took on your regulatory affairs role at Bristol Myers Squibb?
- 02What decision in your Bristol Myers Squibb regulatory affairs role would you make differently today, and why?
- 03What has your own work at Bristol Myers Squibb taught you about building a regulatory affairs team?
Reaching Bristol Myers Squibb regulatory affairs leaders
How can I contact one of these Bristol Myers Squibb regulatory affairs leaders?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 1 company: Bristol Myers Squibb, based on profile data retrieved on October 24, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach Bristol Myers Squibb regulatory affairs leaders?
You choose the offer, starting at $5 per person. The offer is what the person receives, and Instant Expert's fee is added on top, so a $100 offer costs you $125. The fee is 20% of what you pay. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these Bristol Myers Squibb regulatory affairs leaders a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. Claude and ChatGPT can do the same through the Instant Expert connector: setup is at /docs/mcp for Claude and /docs/chatgpt for ChatGPT. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal